CNTN (CNTN)

Overview

Tharimmune, Inc. is a clinical-stage biotechnology organization focused on discovering and developing therapeutic solutions for a range of difficult-to-treat diseases, including those that are rare, inflammatory, and related to oncology. Initially known as Hillstream BioPharma, Inc., the company underwent a rebranding to Tharimmune, Inc. in September 2023, marking a new chapter in its mission to advance healthcare. Since its foundation in 2017, Tharimmune has made significant strides in biotechnology and pharmaceutical innovation from its headquarters in Bridgewater, New Jersey. Collaboration plays a key role in Tharimmune's strategy, exemplified by its partnership with Minotaur Therapeutics, Inc., which focuses on the co-development of proprietary targeted biologic therapies.

Products and Services

TH104 - A promising product candidate in Tharimmune's arsenal, specially designed for the treatment of liver-related and other pruritogenic (itch-inducing) inflammatory conditions. This pre-clinical asset showcases the company's commitment to addressing unmet medical needs in the realm of inflammation and immuno-oncology.

TH3215 and TH0059 - These product candidates represent Tharimmune's innovative approach to combating solid tumors. By targeting the peculiarities of tumor biology, TH3215 and TH0059 are being developed to offer novel therapeutic options for cancer patients, reinforcing Tharimmune's dedication to expanding the boundaries of cancer treatment.

TH1940 - A strategic endeavor targeting the programmed cell death protein 1 (PD-1), TH1940 is positioned within the competitive landscape of immuno-oncology. With its focus on one of the immune system's critical regulators, TH1940 embodies Tharimmune's pursuit to harness the body's own defenses to fight cancer.